Drug intelligence / Profile preview

HDDO-17561 + HDDO-17562

Development stage: Unknown
Lead developer: Hyundai Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HDDO-17561 + HDDO-17562 is a combination of two investigational small molecule drugs developed by Hyundai Pharmaceutical, evaluated primarily as a loose combination product compared to the fixed-dose combination HDDO-1756. Its main development focus has been on hyperlipidemias and other endocrine/metabolic disorders. The mechanism of action for this combination has not been disclosed, and it is not approved for any indication. Clinical evaluation has included bioequivalence and safety/pharmacokinetics studies in phase 1 trials involving healthy adult volunteers[1][3][5].

Beyond the preview

Go deeper on HDDO-17561 + HDDO-17562.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDDO-17561 + HDDO-17562.

Explore the full profile